Cardiac Troponin I and Cardiovascular Risk in Patients With Chronic Obstructive Pulmonary Disease

Philip D Adamson, Julie A Anderson, Robert D Brook, Peter M A Calverley, Bartolome R Celli, Nicholas J Cowans, Courtney Crim, Ian J Dixon, Fernando J Martinez, David E Newby, Jørgen Vestbo, Julie C Yates, Nicholas L Mills, Philip D Adamson, Julie A Anderson, Robert D Brook, Peter M A Calverley, Bartolome R Celli, Nicholas J Cowans, Courtney Crim, Ian J Dixon, Fernando J Martinez, David E Newby, Jørgen Vestbo, Julie C Yates, Nicholas L Mills

Abstract

Background: Patients with chronic obstructive pulmonary disease (COPD) have increased risk of cardiovascular events.

Objectives: This study evaluated the association between high-sensitivity cardiac troponin I concentration and cardiovascular events in patients with COPD and heightened cardiovascular risk.

Methods: In a double-blind randomized controlled trial, 16,485 patients with COPD and cardiovascular disease or risk factors were randomized to once daily inhaled placebo, fluticasone furoate (100 μg), vilanterol (25 μg), or their combination. Plasma high-sensitivity cardiac troponin I concentrations were measured in a subgroup of 1,599 patients. Outcomes were on-treatment cardiovascular events and COPD exacerbations over a median of 18 months, and cardiovascular death over a median of 27 months.

Results: Baseline plasma cardiac troponin I concentrations were above the limit of detection (1.2 ng/l) in 1,542 (96%) patients. Concentrations were unaffected by inhaled therapies at 3 months (p > 0.05). Compared with the lowest quintile (cardiac troponin <2.3 ng/l), patients in the highest quintile (≥7.7 ng/l) were at greater risk of cardiovascular events (hazard ratio [HR] 3.7; 95% confidence interval [CI]: 1.3 to 10.1; p = 0.012) and cardiovascular death (HR: 20.1; 95% CI: 2.4 to 165.2; p = 0.005) after adjustment for risk factors. By contrast, there were no differences in exacerbations between quintiles (HR: 1.1; 95% CI: 0.8 to 1.5; p = 0.548).

Conclusions: In patients with COPD and heightened cardiovascular risk, plasma cardiac troponin I concentrations are a specific and major indicator of future cardiovascular events and cardiovascular death. Inhaled therapies did not affect cardiac troponin I concentrations consistent with their neutral effect on mortality and cardiovascular outcomes. (Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease [SUMMIT]; NCT01313676).

Keywords: cardiac troponin; cardiovascular risk; chronic obstructive pulmonary disease.

Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.

Figures

Figure 1
Figure 1
Baseline High-Sensitivity Cardiac Troponin and Risk of CV Composite Events, CV Death, and COPD Exacerbations Patients were grouped into quintiles based on their baseline cardiac troponin I concentrations. Compared with the lowest quintile ((A) and CV death (B). By contrast, there was no difference between the highest and lowest quintiles in the risk of moderate or severe COPD exacerbations (C). CI = confidence interval; COPD = chronic obstructive pulmonary disease; CV = cardiovascular.
Central Illustration
Central Illustration
High-Sensitivity Cardiac Troponin I Concentration Is a Strong, Independent, and Specific Predictor of CV Death in Patients With COPD The association between baseline high-sensitivity cardiac troponin I and CV death (orange) and COPD exacerbations (blue) was examined using cardiac troponin as a continuous variable. Hazard ratios are compared with the median troponin concentration in the first quintile (1.7 ng/l) and are adjusted for age, sex, previous myocardial infarction, hypertension, and exacerbation history. Shaded areas represent 95% confidence intervals. COPD = chronic obstructive pulmonary disease; CV = cardiovascular.
Figure 2
Figure 2
High-Sensitivity Cardiac Troponin at Baseline or 3 Months and Risk of CV Composite Events, CV Death, and COPD Exacerbations Patients were grouped into those who had high-sensitivity cardiac troponin I concentrations (A) and CV death (B). By contrast, there was no difference in COPD exacerbations (C). Abbreviations as in Figure 1.

References

    1. Lozano R., Naghavi M., Foreman K. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095–2128.
    1. Mullerova H., Agusti A., Erqou S., Mapel D.W. Cardiovascular comorbidity in COPD: systematic literature review. Chest. 2013;144:1163–1178.
    1. Woodruff P.G. Double-edged sword? Long-acting bronchodilators in chronic obstructive pulmonary disease. JAMA Intern Med. 2013;173:1184–1185.
    1. Bresalier R.S., Sandler R.S., Quan H. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352:1092–1102.
    1. Everett B.M. Cardiac troponin as a novel tool for cardiovascular risk prediction in ambulatory populations. Trends Cardiovasc Med. 2017;27:41–47.
    1. Omland T., de Lemos J.A., Sabatine M.S. A sensitive cardiac troponin T assay in stable coronary artery disease. N Engl J Med. 2009;361:2538–2547.
    1. Omland T., Pfeffer M.A., Solomon S.D. Prognostic value of cardiac troponin I measured with a highly sensitive assay in patients with stable coronary artery disease. J Am Coll Cardiol. 2013;61:1240–1249.
    1. de Lemos J.A., Drazner M.H., Omland T. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA. 2010;304:2503–2512.
    1. deFilippi C.R., de Lemos J.A., Christenson R.H. Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. JAMA. 2010;304:2494–2502.
    1. Eggers K.M., Venge P., Lindahl B., Lind L. Cardiac troponin I levels measured with a high-sensitive assay increase over time and are strong predictors of mortality in an elderly population. J Am Coll Cardiol. 2013;61:1906–1913.
    1. Zeller T., Tunstall-Pedoe H., Saarela O. High population prevalence of cardiac troponin I measured by a high-sensitivity assay and cardiovascular risk estimation: the MORGAM Biomarker Project Scottish Cohort. Eur Heart J. 2014;35:271–281.
    1. Ford I., Shah A.S., Zhang R. High-sensitivity cardiac troponin, statin therapy, and risk of coronary heart disease. J Am Coll Cardiol. 2016;68:2719–2728.
    1. Vestbo J., Anderson J., Brook R.D. The Study to Understand Mortality and Morbidity in COPD (SUMMIT) study protocol. Eur Respir J. 2013;41:1017–1022.
    1. Vestbo J., Anderson J.A., Brook R.D. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet. 2016;387:1817–1826.
    1. Calverley P.M., Anderson J.A., Celli B. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775–789.
    1. Salpeter S.R., Ormiston T.M., Salpeter E.E. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest. 2004;125:2309–2321.
    1. Brook R.D., Anderson J.A., Calverley P.M. Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk. Heart. 2017;103:1536–1542.
    1. Apple F.S., Collinson P.O. Analytical characteristics of high-sensitivity cardiac troponin assays. Clin Chem. 2012;58:54–61.
    1. Shah A.S., Griffiths M., Lee K.K. High sensitivity cardiac troponin and the under-diagnosis of myocardial infarction in women: prospective cohort study. BMJ. 2015;350:g7873.
    1. Royston P., Sauerbrei W. A new approach to modelling interactions between treatment and continuous covariates in clinical trials by using fractional polynomials. Stat Med. 2004;23:2509–2525.
    1. Shah A.S., Anand A., Sandoval Y. High-sensitivity cardiac troponin I at presentation in patients with suspected acute coronary syndrome: a cohort study. Lancet. 2015;386:2481–2488.
    1. Hilde J.M., Skjorten I., Grotta O.J. Right ventricular dysfunction and remodeling in chronic obstructive pulmonary disease without pulmonary hypertension. J Am Coll Cardiol. 2013;62:1103–1111.
    1. Orde M.M. Raised troponin levels in COPD: a possible mechanism. Heart. 2013;99:894.
    1. Neukamm A.M., Hoiseth A.D., Hagve T.A., Soyseth V., Omland T. High-sensitivity cardiac troponin T levels are increased in stable COPD. Heart. 2013;99:382–387.
    1. Neukamm A., Einvik G., Didrik Hoiseth A. The prognostic value of measurement of high-sensitive cardiac troponin T for mortality in a cohort of stable chronic obstructive pulmonary disease patients. BMC Pulm Med. 2016;16:164.
    1. Brekke P.H., Omland T., Holmedal S.H., Smith P., Soyseth V. Troponin T elevation and long-term mortality after chronic obstructive pulmonary disease exacerbation. Eur Respir J. 2008;31:563–570.
    1. Wannamethee S.G., Shaper A.G., Papacosta O. Lung function and airway obstruction: associations with circulating markers of cardiac function and incident heart failure in older men-the British Regional Heart Study. Thorax. 2016;71:526–534.
    1. Piepoli M.F., Hoes A.W., Agewall S. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Eur Heart J. 2016;37:2315–2381.
    1. Bibbins-Domingo K., Grossman D.C., Curry S.J. Statin use for the primary prevention of cardiovascular disease in adults: US Preventive Services Task Force recommendation statement. JAMA. 2016;316:1997–2007.
    1. Bibbins-Domingo K. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2016;164:836–845.
    1. Decramer M., Janssens W. Chronic obstructive pulmonary disease and comorbidities. Lancet Respir Med. 2013;1:73–83.
    1. Rajagopalan S., Brook R.D. Mortality from myocardial infarction in chronic obstructive pulmonary disease: minding and mending the 'Gap'. Heart. 2015;101:1085–1086.
    1. Maclay J.D., MacNee W. Cardiovascular disease in COPD: mechanisms. Chest. 2013;143:798–807.
    1. Gershon A., Croxford R., Calzavara A. Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease. JAMA Intern Med. 2013;173:1175–1185.
    1. Mannino D.M. Biomarkers in COPD: the search continues! Eur Respir J. 2015;45:872–874.
    1. Sharma S., Jackson P.G., Makan J. Cardiac troponins. J Clin Pathol. 2004;57:1025–1026.
    1. Paradigm-HF Investigators and Coordinators Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation. 2015;131:54–61.
    1. Everett B.M., Brooks M.M., Vlachos H.E.A. Troponin and cardiac events in stable ischemic heart disease and diabetes. N Engl J Cardiol. 2015;373:610–620.
    1. Lipid Study Investigators Biomarkers in stable coronary heart disease, their modulation and cardiovascular risk: the LIPID biomarker study. Int J Cardiol. 2015;201:499–507.
    1. Everett B.M., Zeller T., Glynn R.J., Ridker P.M., Blankenberg S. High-sensitivity cardiac troponin I and B-type natriuretic Peptide as predictors of vascular events in primary prevention: impact of statin therapy. Circulation. 2015;131:1851–1860.
    1. Chapman A.R., Lee K.K., McAllister D.A. Association of high-sensitivity cardiac troponin I concentration with cardiac outcomes in patients with suspected acute coronary syndrome. JAMA. 2017;318:1913–1924.
    1. Kavsak P.A., Clark L., Jaffe A.S. Effect of repeat measurements of high-sensitivity cardiac troponin on the same sample using the European Society of Cardiology 0-hour/1-hour or 2-hour algorithms for early rule-out and rule-in for myocardial infarction. Clin Chem. 2017;63:1163–1165.
    1. Kavsak P.A., Jaffe A.S., Greene D.N. Total analytic error for low cardiac troponin concentrations (≤10 ng/l) by use of a high-sensitivity cardiac troponin assay. Clin Chem. 2017;63:1043.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi